References
- Aversa F, Tabilio A, Velardi A, et al. Hematopoietic stem cell transplantation from alternative donors for high-risk acute leukemia: the haploidentical option. Curr Stem Cell Res Ther. 2007;2:105–112. doi:https://doi.org/10.2174/157488807779316973.
- Martelli MF, Reisner Y. Haploidentical ‘megadose’ CD34+ cell transplants for patients with acute leukemia. Leukemia. 2002;16:404–405. doi:https://doi.org/10.1038/sj.leu.2402382.
- Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood. 1997;89:3864–3872.
- Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23:3447–3454. doi:https://doi.org/10.1200/jco.2005.09.117.
- Wang Y, Liu D-H, Liu K-Y, et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer. 2013;119:978–985. doi:https://doi.org/10.1002/cncr.27761.
- Huang X-J, Liu D-H, Liu K-Y, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006;38:291–297. doi:https://doi.org/10.1038/sj.bmt.1705445.
- Chang YJ, Huang XJ. Haploidentical stem cell transplantation: anti-thymocyte globulin-based experience. Semin Hematol. 2016;53:82–89. doi:https://doi.org/10.1053/j.seminhematol.2016.01.004.
- O’Donnell P, Raj K, Pagliuca A. High fever occurring 4 to 5 days post-transplant of haploidentical bone marrow or peripheral blood stem cells after reduced-intensity conditioning associated with the use of post-transplant cyclophosphamide as prophylaxis for graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21:197–198. doi:https://doi.org/10.1016/j.bbmt.2014.10.008.
- McCurdy SR, Muth ST, Tsai H-L, et al. Early fever after haploidentical bone marrow transplantation correlates with class II HLA-mismatching and myeloablation but not outcomes. Biol Blood Marrow Transplant. 2018;24:2056–2064. doi:https://doi.org/10.1016/j.bbmt.2018.06.004.
- Solomon SR, Sizemore CA, Sanacore M, et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant. 2012;18:1859–1866. doi:https://doi.org/10.1016/j.bbmt.2012.06.019.
- Powles RL, Kay HEM, Clink HM, et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet. 1983;321:612–615. doi:https://doi.org/10.1016/s0140-6736(83)91793-2.
- Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–195. doi:https://doi.org/10.1182/blood-2014-05-552729.
- Maude SL, Teachey DT, Porter DL, et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125:4017–4023. doi:https://doi.org/10.1182/blood-2014-12-580068.
- Giavridis T, van der Stegen SJC, Eyquem J, et al. CAR t cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24:731–738. doi:https://doi.org/10.1038/s41591-018-0041-7.
- Imus PH, Blackford AL, Bettinotti M, et al. Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2019;25:2431–2437. doi:https://doi.org/10.1016/j.bbmt.2019.07.027.
- Abboud R, Keller J, Slade M, et al. Severe cytokine-release syndrome after T cell–replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti–IL-6 therapy is safe and well tolerated. Biol Blood Marrow Transplant. 2016;22:1851–1860. doi:https://doi.org/10.1016/j.bbmt.2016.06.010.
- Salas MQ, Lam W, Al-Shaibani Z, et al. Dual T cell depletion with anti-thymocyte globulin and post-transplant cyclophosphamide results in low rates of cytokine release syndrome in peripheral blood haplo-hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25:e387–e388. doi:https://doi.org/10.1016/j.bbmt.2019.09.013.
- Arber DA, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405. doi:https://doi.org/10.1182/blood-2016-03-643544.
- Sullivan KM, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250–259.
- Przepiorka D, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–828.
- Wu Q, et al. Comparison of outcomes of idarubicin intensified TBI–CY and traditional TBI–CY conditioning regimen for high-risk acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A single center experience. Leuk Res. 2015;39:1192–1200. doi:https://doi.org/10.1016/j.leukres.2015.08.015.
- Hong M, Wu Q, Hu C, et al. Idarubicin-intensified BUCY2 regimens may lower relapse rate and improve survival in patients undergoing allo-SCT for high-risk hematological malignancies: a retrospective analysis. Bone Marrow Transplant. 2012;47:196–202. doi:https://doi.org/10.1038/bmt.2011.66.
- Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–1633. doi:https://doi.org/10.1016/j.bbmt.2009.07.004.
- Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625–638. doi:https://doi.org/10.1016/j.bbmt.2018.12.758.
- Spitzer TR. Engraftment syndrome: double-edged sword of hematopoietic cell transplants. Bone Marrow Transplant. 2015;50:469–475. doi:https://doi.org/10.1038/bmt.2014.296.
- Armand P, Kim HT, Logan BR, et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood. 2014;123:3664–3671. doi:https://doi.org/10.1182/blood-2014-01-552984.
- Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094–1097. doi:https://doi.org/10.1086/339329.
- Patterson TF, Thompson GR, Denning DW, et al. Executive summary: practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63:433–442. doi:https://doi.org/10.1093/cid/ciw444.
- Solán L, et al. Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide. Hematol Oncol. 2020; doi:https://doi.org/10.1002/hon.2772.
- Abid MB, et al. Severity of cytokine release syndrome and its association with infections after T cell-replete haploidentical related donor transplantation. Biol Blood Marrow Transplant. 2020; doi:https://doi.org/10.1016/j.bbmt.2020.06.006.
- Mariotti J, Taurino D, Marino F, et al. Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide. Cancer Med. 2020;9:52–61. doi:https://doi.org/10.1002/cam4.2607.
- Raj RV, Hamadani M, Szabo A, et al. Peripheral blood grafts for T cell–replete haploidentical transplantation increase the incidence and severity of cytokine release syndrome. Biol Blood Marrow Transplant. 2018;24:1664–1670. doi:https://doi.org/10.1016/j.bbmt.2018.04.010.
- Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509–1518. doi:https://doi.org/10.1056/NEJMoa1215134.
- Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. New Engl J Med. 2006;355:1018–1028. doi:https://doi.org/10.1056/NEJMoa063842.
- Rosenbaum L. Tragedy, perseverance, and chance — the story of CAR-T therapy. N Engl J Med. 2017;377:1313–1315. doi:https://doi.org/10.1056/NEJMp1711886.
- Cho C, Perales MA. Rapid identification of cytokine release syndrome after haploidentical PBSC transplantation and successful therapy with tocilizumab. Bone Marrow Transplant. 2016;51:1620–1621. doi:https://doi.org/10.1038/bmt.2016.229.
- Solh MM, Dickhaus E, Solomon SR. Fevers post infusion of T-cell replete hla mismatched haploidentical hematopoietic stem cells with post-transplant cyclophosphamide: risk factors and impact on transplant outcomes. Bone Marrow Transplant. 2019;54:1756–1763. doi:https://doi.org/10.1038/s41409-019-0522-4.
- Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–1517. doi:https://doi.org/10.1056/NEJMoa1407222.
- Broxmeyer HE, et al. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-γ. J Immunol. 1986;136:4487–4495.
- SATO T, MISAGO M, SUKADA J-i, et al. Effect of interleukin-4 on the growth of granulocyte-macrophage progenitor cells stimulated by hematopoietic growth factors. J UOEH. 1990;12:163–174. doi:https://doi.org/10.7888/juoeh.12.163.
- Katayama K, et al. Antagonistic effects of interleukin 6 and G-CSF in the later stage of human granulopoiesis in vitro. Exp Hematol. 1990;18:390–394.